MPG.eBooks - Search Results

1

Mapping and sequencing the human genome

Published 1988

National Academy Press

Subjects: “...DNA / analysis...”

Read Now

2

Pharmacoeconomic review report: Burosumab (Crysvita), Kyowa Kirin Limited : indication : for the treatment of x-linked hypophosphatemia in adult and pediatric patients one year of...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

3

Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

4

Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

5

Scanning for new evidence on the nutrient content of human milk : a process model for determining age-specific nutrient requirements

Published 2020

National Academies Press

Subjects: “...Nutrients / analysis...”

Read Now

6

CADTH Canadian Drug Expert Committee recommendation: Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

7

Effect of oseltamivir (TamifluR) for the prevention and treatment of influenza during an influenza pandemic

by Mørland, Berit
Published 2005

Norwegian Knowledge Centre for the Health Services

Subjects: “...Cost-Benefit Analysis...”

Read Now

8

CADTH Canadian Drug Expert Committee recommendation: Vedolizumab (Entyvio -- Takeda Canada Inc.) : indication : for the treatment of adult patients with moderately to severely acti...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

9

CADTH Canadian drug expert committee recommendation: Burosumab (Crysvita -- Kyowa Kirin Limited) : indication : treatment of x-linked hypophosphatemia

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

10

Long-term use of ranibizumab for the treatment of age-related macular degeneration : a review of the clinical and cost-effectiveness and guidelines

Published 2014

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

11

Long-term use of ranibizumab for the treatment of age-related macular degeneration : a review of the clinical and cost-effectiveness and guidelines

Published 2014

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

12

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

13

Non-invasive methods for diagnosis and monitoring of liver fibrosis in patients with chronic hepatitis B and C : a review of diagnostic accuracy, clinical effectiveness, cost-effec...

Published 2015

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

14

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

15

Masks for prevention of influenza transmission in acute and long-term care settings : a review of clinical effectiveness, cost-effectiveness and guidelines

by Marchand, Dave K., Argáez, Charlene
Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

16

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

17

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

18

Third-line drugs for type 2 diabetes -- project protocol

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

19

Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Published 2017

CADTH

Subjects: “...Cost-Benefit Analysis...”

Read Now

20

Pharmacoeconomic review report: Sarilumab (Kevzara)

Published 2017

CADTH

Subjects: “...Cost-Benefit Analysis...”

Narrow Search